Novocure (NASDAQ:NVCR) shares surged ~31% premarket Thursday after the oncology company said that a Phase 3 trial for its cancer therapy Tumor Treating Fields (TTFields) reached its primary endpoint ...
Source LinkNovocure (NASDAQ:NVCR) shares surged ~31% premarket Thursday after the oncology company said that a Phase 3 trial for its cancer therapy Tumor Treating Fields (TTFields) reached its primary endpoint ...
Source Link
Comments